CClinicalTrials.gg
Sign In
Status unknownNCT00673647CANDIS-IIUpdated Aug 26, 2009

CANDIS-II: Evaluation of the Cognitive-behavioral Treatment Programme CANDIS

A Phase 3 interventional study of Cognitive-behavioral treatment in Cannabis Use Disorders, sponsored by Technische Universität Dresden. Status unknown at 11 sites in Germany. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2009-08-26.

Sponsored by Technische Universität Dresden · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2009), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Phase 3
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the effectiveness of the cognitive-behavioral treatment program CANDIS among n=450 patients with cannabis use disorders in a mulicenter randomized-controlled clinical trial (n=11 outpatient treatment centers).

02

Conditions studied

  • Cannabis Use Disorders

Browse trials for

Keywords

  • cannabis
  • dependence
  • marijuana
  • CBT
  • efficacy of CBT for cannabis use disorders
03

In context

Marijuana Abuse

517 studies on the registry are indexed under Marijuana Abuse; 114 are open to participants now.

This study's planned enrollment of 450 is above the median of 60 across 421 interventional studies indexed under Marijuana Abuse.

Browse Marijuana Abuse studies →

Lead sponsor

Technische Universität Dresden is the lead sponsor of 237 studies on the registry; 45 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • motivation to change cannabis use
  • age 16 or older
  • current (12 mth) regular cannabis use (at least 2 days a week)
  • informed consent to the study procedures and assessments

Exclusion criteria

Exclusion Criteria:

  • current alcohol or any illicit drug dependence syndrome according to DSM-IV other than due to cannabis
  • lifetime history of any psychotic disorder
  • current severe episode of Major depression
  • current panic-agoraphobic disorder (severe)
  • severe learning disability, brain damage or pervasive developmental disorder
  • currently acute suicidality
  • not fluent in german language
  • any other current treatment for cannabis use disorders
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    1

    Individual psychotherapy including cognitive behavioral components, motivational interviewing techniques and case management

    Behavioral: Cognitive-behavioral treatment

  • No intervention
    2

    Delayed treatment control group

Interventions

  • BehavioralCognitive-behavioral treatment

    10 sessions of individual psychotherapy including cognitive-behavioral treatment, motivational enhancement and a psychosocial problem training.

    Also known as: delayed treatment control group

06

What researchers measure

Primary outcomes

  1. abstinence, defined as no evidence of cannabis use during the past 4 weeks as evidenced by self report and a negative urine screen; number of times a cannabis product was used in the past 4 weeks; retention rate

    Time frame: at the end of treatment

07

Study locations

11 sites
  • Psychosoziale Beratungs- und Behandlungsstelle für Suchtgefährdete und -kranke
    Bautzen, 02625, Germany
  • LogIn Jugend- und Suchtberatung
    Berlin, 10585, Germany
  • Therapieladen e.V.
    Berlin, 10783, Germany
  • Jugend- und Drogenberatung Braunschweig
    Braunschweig, 38102, Germany
  • Jugend- und Drogenberatung Dresden
    Dresden, 01219, Germany
  • Die Boje - Suchtberatung und Behandlung
    Hamburg, 20146, Germany
  • Drobs Hannover
    Hannover, 30159, Germany
  • Caritas-Fachambulanz für junge Suchtkranke
    Muenchen, 80335, Germany
  • Suchtambulanz der LWL-Klinik Münster
    Muenster, 48147, Germany
  • Caritas Fachambulanz für Suchtprävention und Rehabilitation Osnabrück
    Osnabrueck, 49074, Germany
  • Release Stuttgart e.V. & Ambulante Beratungs- und Behandlungsstelle Klinikum Stuttgart
    Stuttgart, 70190, Germany
08

References and documents

Publications

  • Hoch E, Buhringer G, Pixa A, Dittmer K, Henker J, Seifert A, Wittchen HU. CANDIS treatment program for cannabis use disorders: findings from a randomized multi-site translational trial. Drug Alcohol Depend. 2014 Jan 1;134:185-193. doi: 10.1016/j.drugalcdep.2013.09.028. Epub 2013 Oct 8. PubMed 24176199 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 26, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00673647
Lead sponsor
Technische Universität Dresden
Collaborators
Federal Ministry of Health
First posted
May 7, 2008
Start date
May 2008
Primary completion
Oct 2009 (estimated)
Completion
Oct 2009 (estimated)
Last update
Aug 26, 2009

Study contacts

Hans-Ulrich Wittchen, PhD
study director · Technische Universitaet Dresden
Gerhard Buehringer, PhD
study director · Technische Universitaet Dresden
Eva Hoch, PhD
principal investigator · Technische Universitaet Dresden

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Marijuana Abuse→

Other studies from this sponsor

Technische Universität Dresden

Start the discussion